About this episode

This episode discusses the investment potential of Harrow, a pharma company, following a recent stock drop despite strong growth prospects.

Healthcare investing isn't always about blockbuster drugs – sometimes the best opportunities hide in profitable niches. In this episode, we sit down with Finimize analyst Russell Burns to dig into Harrow, an ophthalmology pharma company whose stock has dropped 30% in recent weeks despite a still-strong growth outlook. With shares up 400% over five years – dwarfing the S&P 500 – Russell explains why this pullback might be the entry point investors have been waiting for. Try Finimize ...

People in this episode

Host: Finimize

Guest: Russell Burns

Topics covered

• healthcare investing
• ophthalmology
• pharma stocks
• investment opportunities
• market analysis

Keywords

• Harrow
• ophthalmology
• pharma stock
• investment
• Russell Burns
• S&P 500
• growth outlook
• market pullback

Mentioned in this episode

Organizations: Harrow, S&P 500

More episodes of Investor Intelligence

• How Our Investing Ideas Have Help Up: May 2026 · May 6, 2026 · 28 min
• The Global Grid Upgrade, And How To Invest In It · April 22, 2026 · 22 min
• From The Vault: What 200 Years Of Market History Can Teach You About Investing · April 15, 2026 · 18 min
• Why Gold Looks Seriously Attractive Right Now · April 9, 2026 · 11 min
• How Our Investing Ideas Have Held Up: April 2026 · April 2, 2026 · 17 min
• This Little-Known Defense Stock Is Seeing Big Growth – And Room To Run · March 25, 2026 · 14 min

Explore listener stats, chart rankings, contacts and more on the Investor Intelligence podcast page.